The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
Trending
- Bernard-Henri Levy Watches With Anguish as France Burns
- The French Republic Is Defenseless
- Economic Woes Transform Midwest Into 2026 Battleground
- Closing Momentum Shifting to Republicans
- Republicans Will Go To Prison If Dems Win in Nov
- A Diagnosis Is Not a Destiny. Neither Is Conventional Wisdom
- Trump Doing Everything He Can To Shake Down Voters
- Rubio’s Evaluation of the West & of America